Keith Kerr, BSc, MB, ChB, University of Aberdeen, Aberdeen, UK shares his thoughts on biomarker testing for antibody-drug conjugates (ADCs). ADCs function via recognition of tumor-specific antigens. Upon binding with the targeted cell surface antigen, the ADC is internalized by the tumor cell and the chemotherapeutic agent in released. Prof. Kerr discusses the dependency of biomarkers on the efficacy of ADCs, including HER2, HER3 and Trop2. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
